Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating reissued by equities research analysts at BMO Capital Markets in a note issued to investors on Monday. They currently have a $16.00 price target on the specialty pharmaceutical company’s stock. BMO Capital Markets’ price target would suggest a potential upside of 40.23% from the company’s current price.

A number of other brokerages have also recently issued reports on VRX. Stifel Nicolaus reiterated a “buy” rating and set a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating and set a $18.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, July 14th. Cantor Fitzgerald set a $23.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “buy” rating in a report on Friday, July 28th. ValuEngine upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research upgraded shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Thursday, July 27th. Five investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has an average rating of “Hold” and a consensus target price of $17.56.

Shares of Valeant Pharmaceuticals International (VRX) remained flat at $11.41 during trading on Monday. The company’s stock had a trading volume of 8,654,195 shares. The company’s market capitalization is $3.98 billion. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $24.30. The firm’s 50-day moving average price is $13.60 and its 200-day moving average price is $13.67.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same period in the previous year, the firm posted ($0.88) earnings per share. The business’s revenue was down 7.7% compared to the same quarter last year. Equities research analysts forecast that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Rating Reiterated by BMO Capital Markets” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/30/valeant-pharmaceuticals-international-inc-vrx-rating-reiterated-by-bmo-capital-markets.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was bought at an average price of $14.33 per share, with a total value of $143,300.00. Following the purchase, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.87% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Paulson & CO. Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 12.5% in the 2nd quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after purchasing an additional 294,643 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Valeant Pharmaceuticals International by 9.8% in the 2nd quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock valued at $109,521,000 after purchasing an additional 564,215 shares in the last quarter. CIBC World Markets Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 2.3% in the 2nd quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after purchasing an additional 83,592 shares in the last quarter. Finally, Chou Associates Management Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 29.7% in the 2nd quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock valued at $53,030,000 after purchasing an additional 700,000 shares in the last quarter. 50.21% of the stock is owned by institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.